Intellia Therapeutics (NASDAQ:NTLA) EVP Sells $95,756.37 in Stock

Intellia Therapeutics, Inc. (NASDAQ:NTLA) EVP James Basta sold 10,397 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $95,756.37. Following the completion of the transaction, the executive vice president directly owned 101,528 shares of the company’s stock, valued at $935,072.88. This represents a 9.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Intellia Therapeutics Trading Down 1.1%

Intellia Therapeutics stock opened at $10.41 on Friday. The firm has a market capitalization of $1.21 billion, a P/E ratio of -2.44 and a beta of 2.05. Intellia Therapeutics, Inc. has a twelve month low of $5.90 and a twelve month high of $28.25. The stock’s fifty day simple moving average is $9.44 and its 200-day simple moving average is $12.68.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, November 6th. The company reported ($0.92) EPS for the quarter, topping the consensus estimate of ($1.02) by $0.10. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The firm had revenue of $13.78 million during the quarter, compared to analysts’ expectations of $14.12 million. During the same period in the previous year, the firm posted ($1.34) EPS. Intellia Therapeutics’s revenue for the quarter was up 51.6% on a year-over-year basis. Sell-side analysts predict that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current year.

Analysts Set New Price Targets

NTLA has been the topic of several analyst reports. William Blair cut shares of Intellia Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, October 27th. Wells Fargo & Company reduced their price objective on shares of Intellia Therapeutics from $17.00 to $12.00 and set an “equal weight” rating on the stock in a report on Friday, November 7th. Bank of America decreased their price objective on shares of Intellia Therapeutics from $36.00 to $30.00 and set a “buy” rating for the company in a research report on Monday, October 27th. Evercore ISI set a $8.00 target price on shares of Intellia Therapeutics and gave the stock an “in-line” rating in a research note on Tuesday, November 11th. Finally, Guggenheim cut Intellia Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, October 27th. Ten investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, Intellia Therapeutics currently has an average rating of “Hold” and an average price target of $17.00.

Institutional Investors Weigh In On Intellia Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Headlands Technologies LLC purchased a new stake in Intellia Therapeutics in the second quarter valued at $26,000. Blue Bell Private Wealth Management LLC acquired a new stake in shares of Intellia Therapeutics during the third quarter worth about $30,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Intellia Therapeutics in the 3rd quarter valued at about $30,000. Whipplewood Advisors LLC boosted its position in shares of Intellia Therapeutics by 114,900.0% in the 2nd quarter. Whipplewood Advisors LLC now owns 3,450 shares of the company’s stock valued at $32,000 after purchasing an additional 3,447 shares during the period. Finally, Advisory Services Network LLC acquired a new stake in shares of Intellia Therapeutics in the 3rd quarter valued at about $33,000. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.